Gilead Sciences Stock Poised for More Upside
Gilead Sciences (GILD) shares have risen approximately 35% since Barron's last recommended them a year ago, driven by a robust portfolio of HIV and oncology medications contributing to stable revenue.
Gilead Sciences (GILD) shares have risen approximately 35% since Barron's last recommended them a year ago, driven by a robust portfolio of HIV and oncology medications contributing to stable revenue.